Gu C - Search Results

1

Inhibition of VCP modulates NF-κB signaling pathway to suppress multiple myeloma cell proliferation and osteoclast differentiation.

Wei R, Cao Y, Wu H, Liu X, Jiang M, Luo X, Deng Z, Wang Z, Ke M, Zhu Y, Chen S, Gu C, Yang Y. Wei R, et al. Among authors: gu c. Aging (Albany NY). 2023 Aug 21;15(16):8220-8236. doi: 10.18632/aging.204965. Epub 2023 Aug 21. Aging (Albany NY). 2023. PMID: 37606987 Free PMC article.

2

BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.

Yang Y, Gu C, Luo C, Li F, Wang M. Yang Y, et al. Among authors: gu c. Med Oncol. 2015 Mar;32(3):81. doi: 10.1007/s12032-015-0542-x. Epub 2015 Feb 20. Med Oncol. 2015. PMID: 25698537

3

FOXM1 is a therapeutic target for high-risk multiple myeloma.

Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. Gu C, et al. Leukemia. 2016 Apr;30(4):873-82. doi: 10.1038/leu.2015.334. Epub 2015 Dec 9. Leukemia. 2016. PMID: 26648534 Free PMC article.

4

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.

Gu C, Feng L, Peng H, Yang H, Feng Z, Yang Y. Gu C, et al. Oncotarget. 2016 Jan 26;7(4):4559-69. doi: 10.18632/oncotarget.6610. Oncotarget. 2016. PMID: 26683226 Free PMC article.

5

Deciphering bacterial community changes in zucker diabetic fatty rats based on 16S rRNA gene sequences analysis.

Gu C, Yang Y, Xiang H, Li S, Liang L, Sui H, Zhan L, Lu X. Gu C, et al. Oncotarget. 2016 Aug 2;7(31):48941-48952. doi: 10.18632/oncotarget.10597. Oncotarget. 2016. PMID: 27418144 Free PMC article.

6

BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling.

Gu C, Peng H, Lu Y, Yang H, Tian Z, Yin G, Zhang W, Lu S, Zhang Y, Yang Y. Gu C, et al. Oncotarget. 2017 May 23;8(34):56858-56867. doi: 10.18632/oncotarget.18096. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915637 Free PMC article.

7

Chromosomal instability and acquired drug resistance in multiple myeloma.

Wang W, Zhang Y, Chen R, Tian Z, Zhai Y, Janz S, Gu C, Yang Y. Wang W, et al. Among authors: gu c. Oncotarget. 2017 Sep 11;8(44):78234-78244. doi: 10.18632/oncotarget.20829. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100463 Free PMC article. Review.

8

MK2 is a therapeutic target for high-risk multiple myeloma.

Gu C, Cheng H, Yang H, Bian Y, Wang Y, Zhang Y, Pisano M, Hu G, Yang Y. Gu C, et al. Haematologica. 2021 Jun 1;106(6):1774-1777. doi: 10.3324/haematol.2017.182121. Haematologica. 2021. PMID: 29567777 Free PMC article. No abstract available.

9

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.

Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Gu C, et al. BMC Cancer. 2018 Nov 21;18(1):1152. doi: 10.1186/s12885-018-5015-0. BMC Cancer. 2018. PMID: 30463534 Free PMC article.

10

Iron metabolism and its contribution to cancer (Review).

Chen Y, Fan Z, Yang Y, Gu C. Chen Y, et al. Among authors: gu c. Int J Oncol. 2019 Apr;54(4):1143-1154. doi: 10.3892/ijo.2019.4720. Epub 2019 Feb 20. Int J Oncol. 2019. PMID: 30968149 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,644 results

Search Page